|
|
|
| Webinar: Understanding the Impact of IVT mRNA Impurities on Cellular Responses | Not all mRNA is created equal. But how much do impurities really impact therapeutic performance? Join Roche experts to explore how IVT mRNA impurities influence translation efficiency, reactogenicity, and cellular responses. Discover advanced analytical techniques for identifying critical impurities and learn how connecting purity profiles with biological functionality can strengthen quality control strategies for RNA-based therapeutics. Click here to learn more. |
|
|
|
|
By Anna Rose Welch, Advancing RNA | Fortunately, as my conversation with ParcelBio CEO David Weinberg emphasized, there’s still a lot of room to grow in terms of what our RNA-based products can be and how they can perform. Here in part 2 of this two-part article, Weinberg walks me through how ParcelBio is approaching this market and helping define what a competitive mRNA product will look like in the in vivo CAR-T space. | |
|
|
|
By Advancing RNA Live | This Advancing RNA Live panel, comprising Elaine Peters, Ilya Shestopalov, and Philippe Talaga, addresses which mRNA-LNP attributes could benefit the most from orthogonal extended characterization. | |
|
|
|
By David R. Tabatadze, Ph.D., ZATA Pharmaceuticals, Inc. | How can we make the passenger strand easier to reject while keeping the siRNA duplex sufficiently stable before it reaches the machinery that activates it? | |
|
|
|
|
|
| Screening T7 Polymerases To Optimize xRNA Yield And Quality | Article | By Jing Zhu, Ph.D., Recipharm Advanced Bio | Discover how the evolution of T7 polymerase is optimizing in vitro transcription for RNA therapeutics. Learn to balance performance, cost, and supply to make smart choices for your xRNA manufacturing. |
|
|
|
| Manufacturing Strategies For mRNA Vaccines And Therapeutics | White Paper | By Laurens Vergauwen, Dr. Nargisse El Hajjami, et al., MilliporeSigma | mRNA has emerged as a promising modality offering a great deal of versatility for a wide range of therapeutics and vaccines with its use of non-viral delivery systems. |
|
|
| mRNA Research Services To Accelerate Your Project | Q&A | By Ilaria Pettinati, Ph.D., and Alexander Schwenger, Ph.D., Lonza | Codon optimization accelerates early mRNA projects by balancing manufacturability, stability, and expression upfront, shaping research toward scalable, low-immunogenicity candidates. |
|
|
|
|
|
|
|
|